Products for Research Use Only

Evolocumab

CAT: 0804-HY-P9930-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9930-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation[1][2][3].
CAS Number
1256937-27-5
Product Name Alternative
AMG 145
UNSPSC
12352203
Target
NF-κB; Ser/Thr Protease; Toll-like Receptor (TLR)
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/evolocumab.html
Purity
98.40
Solubility
H2O
Smiles
[Evolocumab]
Molecular Weight
(141.8 kDa)
References & Citations
[1]Fala L, et, al. Repatha (Evolocumab) : Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9 (Spec Feature) :136-9.|[2]Zhou Q, et al. Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions. J Diabetes Complications. 2023 Oct;37 (10) :108593.|[3]Safaeian L, et al. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress. Arch Physiol Biochem. 2022 Dec;128 (6) :1681-1686.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched

Popular Products